10/9
02:40 pm
viri
Virios Therapeutics, Inc. (NASDAQ: VIRI) had its price target raised by analysts at HC Wainwright from $0.20 to $5.00. They now have a "neutral" rating on the stock.
Neutral
Report
Virios Therapeutics, Inc. (NASDAQ: VIRI) had its price target raised by analysts at HC Wainwright from $0.20 to $5.00. They now have a "neutral" rating on the stock.
10/7
12:18 pm
viri
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, NAPA, VIRI on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, NAPA, VIRI on Behalf of Shareholders
10/7
08:44 am
viri
VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders
High
Report
VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders
10/7
07:50 am
viri
Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics [Seeking Alpha]
High
Report
Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics [Seeking Alpha]
10/7
07:18 am
viri
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX") [Financial Post (Toronto, Ontario, Canada)]
High
Report
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX") [Financial Post (Toronto, Ontario, Canada)]
10/7
07:05 am
viri
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
High
Report
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)